Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) launched IM8 Daily Ultimate Essentials PRO on February 23, 2026 — a clinical‑grade reformulation with up to 733% greater potency across 11 nutrients, new saffron nootropic, and bioactive vitamin upgrades.
The PRO formula adds two flavours (Mango + Passionfruit; Lemon + Orange), keeps the same price for new and existing customers, and auto‑upgrades subscribers at their next delivery. Product claims include >10,000 five‑star reviews, >670,000 purchases, and >20 million servings. Full supplement facts available at the product page.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million in escrow.
As of Feb 15, 2026, total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; alternative assets $35.2M). The company reports zero outstanding debt and will report Q4 and full-year 2025 results pre-market on Feb 18, 2026.
Prenetics (NASDAQ: PRE) reported record FY2025 results: total revenue $92.4M (up ~480% YoY) and Q4 revenue of $36.6M (+55% QoQ). IM8 reached $10.0M monthly revenue in Dec 2025 and $120M ARR within 12 months, contributing $60.1M in FY2025.
Strategic divestitures (ACT Genomics, Europa, Insighta) boosted total adjusted liquidity to $171.1M as of Feb 15, 2026, with zero debt. Company reiterated 2026 IM8 revenue guidance of $180–$200M.
Prenetics (NASDAQ: PRE) appointed Dr. Darshan Shah to its Board of Directors, effective February 16, 2026. Dr. Shah joins the Audit, Compensation, and Nominating and Corporate Governance Committees and brings clinical longevity expertise, Mayo Clinic surgical training, and consumer product formulation experience highlighted by a Super Bowl Feb 6, 2026 appearance.
He founded Next Health, which plans >30 locations by end of 2026, and will support Prenetics’ IM8 clinical trials and product development efforts.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million held in escrow.
As of Feb 15, 2026 total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; Bitcoin $35.2M). Prenetics reports zero outstanding debt and says proceeds will fund IM8 global expansion, innovation and clinical programs.
Prenetics (NASDAQ: PRE) named Formula 1 driver Ollie Bearman as Global Ambassador and shareholder on Feb 13, 2026. IM8, co-founded by David Beckham, achieved US$100 million ARR in 11 months and cites NSF Certified for Sport® designation for its Daily Ultimate Essentials.
The partnership follows Bearman’s reported use of IM8 products and aligns the brand with elite athletes and a noted Scientific Advisory Board.
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
The company will host an earnings conference call the same day at 10:00 a.m. Eastern Time with a Q&A session; an audio replay will be available on the investor relations website.
Prenetics (NASDAQ: PRE) completed an all-stock sale of its 3PL business Europa on Jan 1, 2026, a divestiture valued at up to $13 million subject to performance milestones. The move is part of a portfolio optimization that followed the $72 million sale of ACT Genomics in October 2025 and aims to concentrate resources on the IM8 health and longevity brand.
The company reported a strong balance sheet with over $70 million cash, 510 BTC, zero debt and approximately $118 million total liquidity. Prenetics projects IM8 revenue of $180–$200 million in 2026 and expects operating-margin improvement beginning in Q2 2026 after eliminating Europa’s ~$6 million operating loss in FY2025.
Prenetics (NASDAQ: PRE) announced that holders representing 86.7% of the 5,445,284 warrants issued in the October 2025 financing have agreed to the Company’s voluntary warrant exchange program.
Approximately 4,720,832 Class A and Class B warrants are expected to be exchanged for about 2.36 million Class C warrants, leaving roughly 3.08 million total outstanding Class A, B and C warrants — a 43.3% reduction from the October 2025 warrants. Full exercise of the ~3.08 million warrants implies ~18.3% dilution to outstanding shares, down from ~32.3% previously.
The Class C warrants carry an $18.00 exercise price, a two-year term (starting when an F-3 resale registration is effective), and a standard forced-redemption feature exercisable if shares trade at or above $21.60 for ten consecutive trading days after effectiveness.
Prenetics (NASDAQ: PRE) announced a capital allocation shift to focus exclusively on its consumer health brand IM8. The company ceased daily Bitcoin purchases on Dec 4, 2025 and will not pursue future Bitcoin acquisitions, while retaining its existing 510 BTC as a treasury reserve. Prenetics reported a strong financial position with over $70 million in cash and cash equivalents and zero debt. IM8 reached over $100 million annualized recurring revenue within 11 months of launch, and the company projects FY2026 IM8 revenue of $180–$200 million. Capital will be directed to IM8 growth activities including product innovation, brand building, talent, working capital, and international expansion.